{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:06Z","timestamp":1792782606597,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Austria"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cardiac transthyretin amyloidosis (ATTR CA) has been increasingly recognized as an important heart failure (HF) entity, and cardiac magnetic resonance (CMR) imaging is a mainstay in the clinical evaluation of this disease. However, studies evaluating the prognostic values of longitudinal data in ATTR CA patients with disease-modifying therapies are lacking. We aimed to assess the prognostic significance of serial quantification of extracellular volume (ECV) in ATTR CA patients treated with tafamidis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The present study included ATTR CA patients who received\u2009\u2265\u20093 months of tafamidis treatment and underwent baseline and CMR, including ECV quantification. The primary endpoint was a composite of all-cause mortality, cardiac transplantation, or hospitalization due to HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between June 2016 and June 2020, 54 patients were included in the present analysis and were representative of a typical ATTR CA cohort (median age: 76.7 years, male participants: 79.6%). The median time on tafamidis before follow-up CMR was 6.0 months (interquartile range (IQR): 6.0\u20138.3). Participants depicted typical structural changes for ATTR CA patients with markedly elevated ECV (51.4% (IQR: 41.3\u201357.6), normal range: 20\u201332%) and myocardial ventricular hypertrophy (intraventricular septum: 19 mm (16.0\u201322.0), normal range: 5\u201312 mm). Change of ECV was the only parameter among clinical, laboratory, and CMR parameters that was independently associated with the composite endpoint (HR: 1.077, 95% CI: 1.013\u20131.145,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Change of ECV was the only predictor of adverse outcome among clinical, laboratory, and imaging parameters in our cohort of tafamidis-treated ATTR CA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>What is the prognostic significance of serial ECV quantification in transthyretin amyloidosis patients on tafamidis treatment<\/jats:italic>\n                      ?\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Change of ECV is a strong predictor of a combined endpoint consisting of all-cause mortality, cardiac transplantation, or hospitalization due to HF<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Patients with increasing ECV might potentially benefit from a change in amyloid-specific treatment to a different agent<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-11792-x","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:01:50Z","timestamp":1752688910000},"page":"172-181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis"],"prefix":"10.1007","volume":"36","author":[{"given":"Franz","family":"Duca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Poledniczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kronberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Camuz-Ligios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Koschutnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Don\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Badr-Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beitzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-9879","authenticated-orcid":false,"given":"Andreas Anselm","family":"Kammerlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"11792_CR1","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2017","unstructured":"Gillmore JD, Damy T, Fontana M et al (2017) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"11792_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","volume":"132","author":"D Bonderman","year":"2020","unstructured":"Bonderman D, P\u00f6lzl G, Ablasser K et al (2020) Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr 132:742\u2013761","journal-title":"Wien Klin Wochenschr"},{"key":"11792_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nrneph.2013.171","volume":"9","author":"JD Gillmore","year":"2013","unstructured":"Gillmore JD, Hawkins PN (2013) Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 9:574\u2013586","journal-title":"Nat Rev Nephrol"},{"key":"11792_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","volume":"11","author":"F Duca","year":"2018","unstructured":"Duca F, Kammerlander AA, Panzenb\u00f6ck A et al (2018) Cardiac magnetic resonance T(1) mapping in cardiac amyloidosis. JACC Cardiovasc imaging 11:1924\u20131926","journal-title":"JACC Cardiovasc imaging"},{"key":"11792_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19:75","journal-title":"J Cardiovasc Magn Reson"},{"key":"11792_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","volume":"24","author":"R Rettl","year":"2023","unstructured":"Rettl R, Wollenweber T, Duca F et al (2023) Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 24:1019\u20131030","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"11792_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","volume":"23","author":"R Rettl","year":"2022","unstructured":"Rettl R, Mann C, Duca F et al (2022) Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 23:767\u2013780","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"11792_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390:132\u2013142","journal-title":"N Engl J Med"},{"key":"11792_CR9","doi-asserted-by":"crossref","unstructured":"Fontana M, Berk JL, Gillmore JD et al (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392:33\u201344","DOI":"10.1056\/NEJMe2410890"},{"key":"11792_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J et al (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493\u2013502","journal-title":"N Engl J Med"},{"key":"11792_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"11792_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ et al (2020) Cost-Effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 141:1214\u20131224","journal-title":"Circulation"},{"key":"11792_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ehjci\/jead188","volume":"25","author":"F Duca","year":"2023","unstructured":"Duca F, Rettl R, Kronberger C et al (2023) Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry. Eur Heart J Cardiovasc Imaging 25:95\u2013104","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"11792_CR14","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"11792_CR15","doi-asserted-by":"publisher","unstructured":"Nitsche C, Ioannou A, Patel RK et al (2024) Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3354","DOI":"10.1002\/ejhf.3354"},{"key":"11792_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jcmg.2015.11.002","volume":"9","author":"AA Kammerlander","year":"2016","unstructured":"Kammerlander AA, Marzluf BA, Zotter-Tufaro C et al (2016) T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Cardiovasc Imaging 9:14\u201323","journal-title":"JACC Cardiovasc Imaging"},{"key":"11792_CR17","doi-asserted-by":"crossref","unstructured":"Duca F, Kammerlander AA, Zotter-Tufaro C et al (2016) Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging 9:e005277","DOI":"10.1161\/CIRCIMAGING.116.005277"},{"key":"11792_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1532-429X-14-61","volume":"14","author":"P Kellman","year":"2012","unstructured":"Kellman P, Wilson JR, Xue H, Ugander M, Arai AE (2012) Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson 14:63","journal-title":"J Cardiovasc Magn Reson"},{"key":"11792_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","volume":"24","author":"L Chacko","year":"2022","unstructured":"Chacko L, Karia N, Venneri L et al (2022) Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail 24:1700\u20131712","journal-title":"Eur J Heart Fail"},{"key":"11792_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146:1657\u20131670","journal-title":"Circulation"},{"key":"11792_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","volume":"84","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Fumagalli C, Razvi Y et al (2024) Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis. J Am Coll Cardiol 84:43\u201358","journal-title":"J Am Coll Cardiol"},{"key":"11792_CR22","doi-asserted-by":"publisher","unstructured":"Duca F, Rettl R, Kronberger C et al (2023) Myocardial structural and functional changes in cardiac amyloidosis - Insights from a prospective observational patient registry. Eur Heart J Cardiovasc Imaging. https:\/\/doi.org\/10.1093\/ehjci\/jead188","DOI":"10.1093\/ehjci\/jead188"},{"key":"11792_CR23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro A, Kotecha T, Norrington K et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12:810\u2013819","journal-title":"JACC Cardiovasc Imaging"},{"key":"11792_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","volume":"7","author":"A Masri","year":"2025","unstructured":"Masri A, Bhattacharya P, Medoff B et al (2025) A Multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy. JACC CardioOncol 7:282\u2013293","journal-title":"JACC CardioOncol"},{"key":"11792_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1532-429X-16-2","volume":"16","author":"P Kellman","year":"2014","unstructured":"Kellman P, Hansen MS (2014) T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson 16:2","journal-title":"J Cardiovasc Magn Reson"},{"key":"11792_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","volume":"12","author":"AA Robinson","year":"2019","unstructured":"Robinson AA, Chow K, Salerno M (2019) Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging 12:2332\u20132344","journal-title":"JACC Cardiovasc Imaging"},{"key":"11792_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.2015141744","volume":"277","author":"M Fontana","year":"2015","unstructured":"Fontana M, Banypersad SM, Treibel TA et al (2015) Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277:388\u2013397","journal-title":"Radiology"},{"key":"11792_CR28","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","volume":"71","author":"T Kotecha","year":"2018","unstructured":"Kotecha T, Martinez-Naharro A, Treibel TA et al (2018) Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 71:2919\u20132931","journal-title":"J Am Coll Cardiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11792-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T14:02:19Z","timestamp":1765980139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11792-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["11792"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11792-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Franz Duca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: F.D.: Speaker fees and congress support from Bayer, Novartis, Alnylam, Pfizer, and AOP, as well as research grants from the Austrian Society of Cardiology, Pfizer, and Bayer. CL is the Scientific Director of the European School of Radiology (ESOR). The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Franz Duca and Andreas A. Kammerlander have significant statistical expertise. Furthermore, no complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"In a prior study, we evaluated the prognostic significance of ECV quantification in ATTR CA, as well as light chain amyloidosis patients irrespective of treatment (Duca et al [\n                      \n                      ]). The present study tests serial ECV quantification in a well-defined cohort consisting solely of patients on disease-modifying treatment.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}